Results 81 to 90 of about 5,054 (206)

A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab

Journal of Health Economics and Outcomes Research, 2020
# Background Psoriasis is a chronic inflammatory skin condition that impacts quality of life and requires long-term treatment and effective symptom management.
Kristian Garn Du Jardin, Pepi Hurtado Lopez, Mette Lange, Rachael McCool, Silvia Maeso Naval, Sandra Quickert   +5 more
doaj   +1 more source

Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Background Psoriatic arthritis (PsA) is a chronic inflammatory disease with complex pathophysiology. Despite advancements in biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), treatment responses remain suboptimal for many patients.
Mengduan Pang, Ling Li, Qi Zhang, Min Zhao   +3 more
wiley   +1 more source

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.

, 2021
OBJECTIVE: Evaluate safety of guselkumab (monoclonal antibody targeting IL-23p19) in psoriatic arthritis (PsA) patients through 1year (1Y) of the Phase-3 DISCOVER-1&2 trials.
Hsia, Elizabeth C, Zhou, Bei, Boehncke, Wolf-Henning, Helliwell, Philip S, Ramachandran, Paraneedharan, Xu, Xie L, Zhuang, Yanli, Rahman, Proton, Mease, Philip J, Gottlieb, Alice B, Shawi, May, Agarwal, Prasheen, McInnes, Iain B, Ritchlin, Christopher T, Kafka, Shelly, Kollmeier, Alexa P, Sheng, Shihong   +16 more
core   +1 more source

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors

Drugs - Real World Outcomes
Background Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food and Drug ...
Jessica A. Walsh, Iris Lin, Ruizhi Zhao, Natalie J. Shiff, Laura Morrison, Bruno Emond, Louise H. Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D. Chakravarty, Philip Mease   +11 more
doaj   +1 more source

Indicators of Suboptimal Treatment Among Patients With Crohn's Disease Treated With Ustekinumab or Risankizumab and Treatment Journey Among Ustekinumab Discontinuers in the United States

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Patients with Crohn's disease (CD) may experience suboptimal response to advanced therapies (ATs), including interleukin (IL)‐12/23 inhibitor ustekinumab and IL‐23 inhibitor risankizumab. In an evolving treatment landscape, this study evaluated indicators of suboptimal treatment with these agents. Methods This retrospective
Freddy Caldera, Maryia Zhdanava, Sumesh Kachroo, Lilian Diaz, Aditi Shah, Fengyi Jiang, Caroline Kerner, Dominic Pilon, Jennifer Seminerio   +8 more
wiley   +1 more source

Efficacy of Advanced Medical Therapies in Patients With Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta‐Analysis

JCC Plus, Volume 1, Issue 5, September 2026.
This systematic review and meta‐analysis quantify absolute outcome differences of advanced therapies in moderate‐to‐severe ulcerative colitis, demonstrating significant benefits in clinical, endoscopic, and histological remission, and establishing a benchmark for evaluating novel or non‐pharmacological treatment strategies.
E. Visser, I. D. van Dijk, G. L. Burchell, W. A. Bemelman, G. R. D'Haens, C. J. Buskens   +5 more
wiley   +1 more source

Efficacy of Interleukin‐12/23 and Interleukin‐23 Inhibitors for Moderately to Severely Active Crohn's Disease in Advanced Treatment Failure Populations: Systematic Review and Network Meta‐Analysis

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Earlier trials of advanced treatments indicated for moderately to severely active Crohn's disease used predominantly re‐randomized induction responder designs, whereas newer treatments were evaluated using treat‐through designs.
Christopher Ma, Marla Dubinsky, Gil Y. Melmed, Namita Joshi, Jenny Griffith, Fernando Aponte, Brooke Kim, Eric B. Collins, Kristen Westerhoff, Remo Panaccione   +9 more
wiley   +1 more source

Impact of Vitamin D Sufficiency on Clinical Outcomes in Patients With IBD Treated With Biologics: A Summary of Observational and Interventional Data

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Vitamin D is increasingly recognised as a modifiable factor influencing immune responses in chronic inflammatory diseases. This short report examines the relationship between vitamin D status and therapeutic outcomes of biologics in patients with inflammatory bowel disease.
Karolina Siayor‐Pietrzak, Aysegül Aksan, Elisa Müller, Jürgen Stein   +3 more
wiley   +1 more source

Guselkumab Treatment ADHEREnce in BulGaria of Patients with Psoriasis—ADHERE-BG Study

Dermatology and Therapy
Introduction Treatment adherence is crucial for managing chronic diseases, including plaque psoriasis. In Bulgaria, patients with plaque psoriasis can receive treatment with reimbursed biologics, such as guselkumab, if they meet National Health Insurance
Grisha S. Mateev, Zdravka V. Demerdjieva, Rumyana K. Yankova, Klimentina D. Gospodinova, Boryana E. Ilieva, Razvigor B. Darlenski   +5 more
doaj   +1 more source